Next-Generation Arrythmia Origin Identification and Treatment System

A novel system for identifying the origin of an arrythmia, utilizing machine learning, deep learning, and cardiac imaging to provide enhanced accuracy and personalized treatment plans.

The original patent, 'Finding the origin of an arrythmia', introduced a method for analyzing results of a cardiac invasive procedure to locate the origin of a single-source arrythmia. However, this method has limitations in terms of accuracy and efficiency. The new inventive concept addresses these limitations by leveraging advanced technologies to provide a more accurate and personalized approach to arrythmia origin identification and treatment.

The next-generation system consists of a cardiac chamber mapping module, a local activation time measurement module, and a machine learning-based origin predictor module. The system generates a 3D map of the heart chamber, measures local activation times at multiple points on the surface, and utilizes a deep learning algorithm to identify the origin of the arrythmia based on the LAT-derived distances and the 3D map. Additionally, the system can integrate with cardiac imaging to display the identified origin on a 3D heart model, enabling real-time tracking and personalized treatment plans.

The new claims introduce the use of machine learning, deep learning, and cardiac imaging to enhance the accuracy of arrythmia origin identification. The integration of these advanced technologies with the original method provides a novel and non-obvious solution that overcomes the limitations of the original patent.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, such as reinforcement learning or transfer learning, or the integration of additional data sources, such as electroanatomical mapping or intracardiac echocardiography. Variations of the system could also include different types of cardiac imaging, such as MRI or CT scans, or the use of robotic-assisted catheter navigation.

The next-generation arrythmia origin identification and treatment system has significant commercial potential in the medical device and healthcare industries. The system's enhanced accuracy and personalized treatment plans could improve patient outcomes and reduce healthcare costs. The target market includes hospitals, clinics, and medical research institutions involved in cardiac invasive procedures and arrythmia treatment.